Overview

Study of Intracoronary CD34+ Cell Administration in Patients With Early Coronary Atherosclerosis

Status:
Active, not recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
How safe and effective are CD34+ cell intracoronary injections for treating coronary endothelial dysfunction (CED)?
Phase:
Phase 1
Details
Lead Sponsor:
Mayo Clinic
Treatments:
Lenograstim
Sargramostim